Underhill Investment Management Lowered D R Horton (DHI) Stake; Ultragenyx Pharmaceutical (RARE)’s Sentiment Is 1.25

April 21, 2018 - By Pete Kolinski

D.R. Horton, Inc. (NYSE:DHI) Logo

Ultragenyx Pharmaceutical Inc (RARE) investors sentiment increased to 1.25 in 2017 Q4. It’s up 0.06, from 1.19 in 2017Q3. The ratio is better, as 70 active investment managers increased or started new equity positions, while 56 trimmed and sold equity positions in Ultragenyx Pharmaceutical Inc. The active investment managers in our database now hold: 42.32 million shares, up from 39.75 million shares in 2017Q3. Also, the number of active investment managers holding Ultragenyx Pharmaceutical Inc in top ten equity positions decreased from 1 to 0 for a decrease of 1. Sold All: 14 Reduced: 42 Increased: 51 New Position: 19.

Underhill Investment Management Llc decreased D R Horton Inc (DHI) stake by 17.18% reported in 2017Q4 SEC filing. Underhill Investment Management Llc sold 41,550 shares as D R Horton Inc (DHI)’s stock declined 13.89%. The Underhill Investment Management Llc holds 200,350 shares with $10.23 million value, down from 241,900 last quarter. D R Horton Inc now has $16.17 billion valuation. The stock decreased 1.71% or $0.75 during the last trading session, reaching $43.01. About 4.85 million shares traded. D.R. Horton, Inc. (NYSE:DHI) has risen 32.44% since April 21, 2017 and is uptrending. It has outperformed by 20.89% the S&P500.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.69 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

The stock increased 0.72% or $0.39 during the last trading session, reaching $54.26. About 403,872 shares traded. Ultragenyx Pharmaceutical Inc. (RARE) has declined 29.39% since April 21, 2017 and is downtrending. It has underperformed by 40.94% the S&P500.

Ratings analysis reveals 0 of Ultragenyx Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Ultragenyx Pharma, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. RARE was included in 2 notes of analysts from November 14, 2016. The rating was downgraded by Citigroup to “Sell” on Monday, November 14. The company was downgraded on Thursday, April 6 by Jefferies.

Iguana Healthcare Management Llc holds 1.51% of its portfolio in Ultragenyx Pharmaceutical Inc. for 50,000 shares. Opaleye Management Inc. owns 90,000 shares or 1.34% of their US portfolio. Moreover, Abingworth Llp has 1.28% invested in the company for 38,100 shares. The Illinois-based Columbia Wanger Asset Management Llc has invested 1% in the stock. Pier Capital Llc, a Connecticut-based fund reported 125,728 shares.

Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on May, 3. They expect $-0.76 EPS, up 53.37% or $0.87 from last year’s $-1.63 per share. After $-2.27 actual EPS reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -66.52% EPS growth.

Analysts await D.R. Horton, Inc. (NYSE:DHI) to report earnings on April, 26 before the open. They expect $0.86 earnings per share, up 43.33% or $0.26 from last year’s $0.6 per share. DHI’s profit will be $323.28M for 12.50 P/E if the $0.86 EPS becomes a reality. After $0.77 actual earnings per share reported by D.R. Horton, Inc. for the previous quarter, Wall Street now forecasts 11.69% EPS growth.

Since February 1, 2018, it had 0 insider purchases, and 17 selling transactions for $3.24 million activity. Hewatt Michael W had sold 3,423 shares worth $143,213 on Thursday, March 1. On Monday, February 12 the insider WHEAT BILL W sold $120,181. On Tuesday, February 20 the insider Allen Barbara K sold $110,794. Murray Michael J had sold 2,598 shares worth $109,505. 11,618 D.R. Horton, Inc. (NYSE:DHI) shares with value of $520,554 were sold by HORTON DONALD R. Auld David V sold $201,812 worth of stock.

Among 25 analysts covering DR Horton Inc (NYSE:DHI), 16 have Buy rating, 0 Sell and 9 Hold. Therefore 64% are positive. DR Horton Inc had 77 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, September 20 by Wedbush. KeyBanc Capital Markets maintained it with “Buy” rating and $41.0 target in Tuesday, August 22 report. The firm has “Outperform” rating by Wedbush given on Wednesday, March 7. The stock of D.R. Horton, Inc. (NYSE:DHI) has “Buy” rating given on Thursday, July 13 by RBC Capital Markets. As per Thursday, February 1, the company rating was maintained by Bank of America. Mizuho maintained D.R. Horton, Inc. (NYSE:DHI) rating on Thursday, February 1. Mizuho has “Hold” rating and $52.0 target. The stock of D.R. Horton, Inc. (NYSE:DHI) has “Buy” rating given on Wednesday, January 17 by UBS. FBN Securities upgraded it to “Sector Perform” rating and $27.50 target in Monday, October 10 report. The rating was downgraded by UBS to “Neutral” on Monday, January 18. On Friday, November 10 the stock rating was maintained by Citigroup with “Neutral”.

D.R. Horton, Inc. (NYSE:DHI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>